The TMVR procedure with SAPIEN M3 involves dock and valve delivery via a percutaneous femoral vein guide sheath.

Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

An analyst earlier this month took aim at what’s behind a big run-up in shares of Irvine medical device maker Edwards Lifesciences Corp.: a new type of heart valve that doesn’t require major surgery.

One of Edwards Lifesciences Corp.’s major projects,developing a heart valve that doesn’t require major surgery,is moving along and gaining notice among analysts. Irvine-based Edwards recently started ...

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

CHICAGO (Reuters) - Edwards Lifesciences Corp said a U.S. regulatory advisory panel will review on July 20 its application to sell a replacement heart valve that spares patients the need for ...

The SAPIEN M3 system received CE Mark in April 2025, making it the world’s first approved transfemoral transcatheter mitral ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

Edwards Lifesciences has secured European approval for its transcatheter tricuspid valve replacement system, which the company described as the first minimally invasive therapy of its kind to receive ...

WASHINGTON (Reuters) - The minimally invasive aortic heart valve replacement system from Edwards Lifesciences Corp performed better than a rival product sold by Medtronic Inc in the first head-to-head ...

NEWBURY, England--(BUSINESS WIRE)--Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic ...